Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
- Conditions
- Solid Tumor, Adult
- Interventions
- Biological: CF33-CD19 IT MonotherapyBiological: CF33-CD19 IV MonotherapyBiological: CF33-CD19 IT CombinationBiological: CF33-CD19 IV Combination
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 50
- Registration Number
- NCT06063317
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
- Conditions
- Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 75
- Registration Number
- NCT05822427
- Locations
- 🇺🇸
Science 37, Inc., Culver City, California, United States
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
- Conditions
- Solid TumorSolid CarcinomaSolid Tumor, AdultCholangiocarcinomaBile Duct CancerMetastatic CancerAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 100
- Registration Number
- NCT05346484
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Highlands Oncology, Springdale, Arkansas, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
- Conditions
- Gastric CancerStomach AdenocarcinomaStomach CancerGastric AdenocarcinomaCancer of StomachGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 7
- Registration Number
- NCT05311176
- Locations
- 🇦🇺
Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
🇦🇺The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung CancerNon Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVLarge Cell Carcinoma LungSquamous Non-small-cell Lung CancerAdenocarcinoma Lung
- Interventions
- Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 1Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 2Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 3Drug: Standard of care chemotherapy
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 24
- Registration Number
- NCT04432207
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
- Prev
- 1
- 2
- Next
News
Imugene's Azer-cel Achieves 75% Response Rate in Phase 1b Trial for Relapsed DLBCL
Imugene's azer-cel, an allogeneic off-the-shelf CAR T therapy, demonstrated a 75% overall response rate with 55% complete response rate in patients with relapsed/refractory diffuse large B-cell lymphoma who had failed multiple prior therapies.
Imugene Secures AU$5.87 Million R&D Tax Refund to Advance Immuno-Oncology Pipeline
Imugene Limited received AU$5.87 million in R&D tax refunds from the Australian Government's incentive program, providing up to 48.5% refundable offset for eligible research activities.
HER-Vaxx Plus Chemotherapy Shows Survival Benefit in HER2-Overexpressing Gastric Cancer
• A phase II trial of HER-Vaxx plus chemotherapy demonstrated a 40% survival benefit compared to chemotherapy alone in patients with HER2-overexpressing gastric cancer. • The HER-Vaxx vaccine induced strong HER2-specific IgG and IgG1 antibody responses, correlating with tumor reduction and inhibition of intracellular phosphorylation. • The vaccine's mechanism of action includes antibody-dependent cellular cytotoxicity (ADCC) and counteraction of immune tolerance effects, enhancing chemotherapy's impact. • The study suggests HER-Vaxx is safe and immunogenic, warranting further evaluation in larger trials and combination therapies for advanced gastric cancer.